Capmatinib and Ledipasvir: Interaction Details

Brand names
Capmatinib
Tabrecta
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Ledipasvir

We don't have a separate drug information page for Ledipasvir. The FDA's drug directory lists it as part of Harvoni (ledipasvir and sofosbuvir). Read the Ledipasvir and Sofosbuvir drug information page → Have a question about Ledipasvir? Ask a pharmacist, free →

What Happens When You Take Capmatinib With Ledipasvir

What can happen when they are taken together (rated Major)

Increased exposure and an increased risk of increased adverse reactions

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Giving capmatinib together with a P-gp substrate raised exposure to the substrate, a change that may intensify the adverse reactions associated with these agents.1 In the case of digoxin, a P-gp substrate, with capmatinib produced a 47% rise in digoxin (0 to inf) and a 74% rise in its .12 Where joint use of capmatinib cannot be avoided with P-gp substrates for which even small shifts in concentration could result in serious adverse reactions, the dosage of the P-gp substrate should be lowered according to its recommendations.1

The Capmatinib and Ledipasvir Interaction, Explained

Capmatinib (Tabrecta) is a lung cancer medicine. Ledipasvir is a hepatitis C medicine, usually given in a combination pill with sofosbuvir. Capmatinib can block a natural "pump" in your body (called ) that helps move ledipasvir out. When that pump is slowed, more ledipasvir may stay in your blood. In theory, that could raise the chance of side effects such as tiredness, headache, or nausea.

This concern is based on how the drugs work, not on studies of people taking these two together. Please keep taking your medicines as prescribed and let your pharmacist or doctor know you take both. Your care team can manage this by checking how you feel and adjusting things if needed.

Mechanism: Capmatinib inhibits -mediated efflux. Ledipasvir is a P-gp , so may increase ledipasvir exposure (, ) and the risk of ledipasvir-related adverse reactions.

  • Magnitude: Not studied with ledipasvir. With digoxin, capmatinib increased AUC by 47% and Cmax by 74%.
  • Onset: Unspecified.
  • Evidence: Theoretical, extrapolated from the P-gp probe data. Severity on file: major.
  • Management: Labeling recommends dose reduction only for P-gp substrates where minimal concentration changes may lead to serious adverse reactions. Ledipasvir is not , so routine dose reduction is not expected. Monitor for ledipasvir/sofosbuvir adverse effects and individualize if coadministration is continued.

See the 2 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Capmatinib and Ledipasvir Interact

The likely mechanism

of -mediated efflux transport by capmatinib

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Capmatinib and Ledipasvir Interaction

When these two medicines are used together, your care team may:

  • Monitor you more closely for side effects of your hepatitis C treatment.
  • Review whether any dose may need to be adjusted and individualized, which is generally reserved for medicines where small level changes could cause serious problems.

What you can do: Keep taking both medicines exactly as prescribed. Make sure your pharmacist and every prescriber know you take both. Tell them about any new or worsening side effects.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Capmatinib or Ledipasvir need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: TABRECTA oral tablets, capmatinib oral tablets

    When capmatinib was given together with digoxin (a ), digoxin (0 to inf) rose by 47% and rose by 74%.1 In a small prospective single-sequence study of adult patients with MET-dysregulated advanced solid tumors refractory to currently available therapies (N=32), of capmatinib and digoxin, relative to digoxin alone, yielded digoxin geometric mean ratios of 1.47 (90% CI, 1.28 to 1.68) for AUC(infinity), 1.63 (90% CI, 1.42 to 1.89) for AUC(last), and 1.74 (90% CI, 1.43 to 2.13) for Cmax.

    The digoxin t(1/2) was likewise longer when capmatinib was coadministered than with digoxin alone (61.4 vs 47 hours), whereas Tmax was unchanged. In this study, capmatinib 400 mg twice daily was administered for 12 days, with a single dose of digoxin 0.25 mg and rosuvastatin 10 mg given on day 12.2

Capmatinib and Ledipasvir: Common Questions

How serious is the Capmatinib and Ledipasvir interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Capmatinib and Ledipasvir interaction managed?

When these two medicines are used together, your care team may: Monitor you more closely for side effects of your hepatitis C treatment. Review whether any dose may need to be adjusted and individualized, which is generally reserved for medicines where small level changes could cause serious problems. What you can do: Keep taking both medicines exactly as prescribed. Make sure your pharmacist and… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Capmatinib and Ledipasvir Interaction

Ask in your own words about taking Capmatinib and Ledipasvir together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (2)

  1. Product Information: TABRECTA(TM) oral tablets, capmatinib oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2020. DailyMed
  2. Grande E, Giovannini M, Marriere E, et al: Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: a phase I, multicentre, open-label, single-sequence drug-drug interaction study. Br J Clin Pharmacol 2021; 87(7):2867-2878.
Was this write-up helpful?

Other Serious Interactions of Capmatinib and Ledipasvir

Also serious with Capmatinib

Also serious with Ledipasvir

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.